Martin Iversen, MD
Family Medicine · Tacoma, WANPI 1427036581
Payments from drug & device makers
Across 139 payments — averaging $13.89 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Amgen$319
- AbbVie$302
- Lilly USA, LLC$209
- AstraZeneca$189
- Johnson & Johnson$146
- Boehringer Ingelheim$142
- plus $624 from 17 others
What the payments were for
- Food & beverage$1,83495%
- Education$965%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Amgen | 27 | $319 |
| AbbVie(2 entities) | 20 | $302 |
| Lilly USA, LLC | 20 | $209 |
| AstraZeneca | 11 | $189 |
| Johnson & Johnson | 9 | $146 |
| Boehringer Ingelheim | 11 | $142 |
| Takeda Pharmaceuticals U.S.A., Inc. | 13 | $111 |
| Astellas Pharma US Inc | 3 | $60 |
| Insulet Corporation | 3 | $59 |
| GSK | 2 | $54 |
| Novo Nordisk | 2 | $38 |
| Abbott | 2 | $36 |
| Novartis | 2 | $35 |
| Pfizer | 2 | $32 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 2 | $30 |
| Amarin Pharma, Inc. | 2 | $30 |
| Regeneron Healthcare Solutions, Inc. | 1 | $26 |
| Merck | 2 | $24 |
| Exact Sciences | 1 | $23 |
| Dexcom, Inc. | 1 | $21 |
| Daiichi Sankyo Inc. | 1 | $21 |
| Alfasigma USA, Inc. | 1 | $13 |
| Sanofi-aventis U.S. LLC | 1 | $11 |
How this compares
$1,930 in reported general payments places this provider in the 90th percentile of 2,275 family medicine providers in Washington.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| JardianceEmpagliflozin | 115 | $134,415 |
| TrulicityDulaglutide | 86 | $125,731 |
| XareltoRivaroxaban | 83 | $103,211 |
| RybelsusSemaglutide | 41 | $65,684 |
| EliquisApixaban | 63 | $64,337 |
| InvokanaCanagliflozin | 59 | $62,895 |
| FarxigaDapagliflozin Propanediol | 76 | $60,364 |
| OzempicSemaglutide | 33 | $56,312 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 46 | $47,369 |
| XifaxanRifaximin | 11 | $37,999 |
| TradjentaLinagliptin | 22 | $31,473 |
| JanuviaSitagliptin Phosphate | 32 | $30,493 |
| Repatha SureclickEvolocumab | 28 | $26,156 |
| MyrbetriqMirabegron | 35 | $26,113 |
| Colesevelam Hcl | 54 | $11,715 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Johnson & JohnsonXarelto, Invokana | $146 | $166,106142 claims |
| Boehringer IngelheimJardiance, Tradjenta | $142 | $165,888137 claims |
| Lilly USA, LLCTrulicity | $209 | $125,73186 claims |
| Novo NordiskRybelsus, Ozempic | $38 | $121,99674 claims |
| PfizerEliquis, Prempro | $32 | $72,21981 claims |
| AstraZenecaFarxiga, Symbicort | $189 | $67,36293 claims |
| GSKTrelegy Ellipta, Arnuity Ellipta | $54 | $57,07366 claims |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLCXifaxan | $30 | $37,99911 claims |
| MerckJanuvia | $24 | $30,49332 claims |
| Astellas Pharma US IncMyrbetriq | $60 | $26,11335 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 2,275 family medicine providers in Washington.
Other family medicine in Tacoma
- James RoscettiTacoma$184K
- Marse McNaughtonTacoma$24K
- Benjamin DyTacoma$15K
- Anton GraschWenatchee$5.3M
- Gaylon KippBellevue$4.8M
- Steven KasterWenatchee$4M
- Angela EakinSpokane$3M
- Jonathan StabenCheney$2.5M
- Emily ZaragozaSeattle$1.9M
- Brad FrandsenPort Orchard$1.7M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.